SYRE – spyre therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

SYRE

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/8

08:15 am

syre

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $45.00 price target on the stock.

Medium Report

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $45.00 price target on the stock.

Report

4/8

07:55 am

syre

Rating for SYRE

Medium Report

Rating for SYRE

Report

4/8

06:25 am

syre

Spyre Therapeutics initiated with an Outperform at Leerink

Medium Report

Spyre Therapeutics initiated with an Outperform at Leerink

Report

3/18

08:08 am

syre

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.

Medium Report

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.

Report

3/18

08:08 am

syre

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.

Medium Report

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.

Report

3/17

07:13 pm

syre

Spyre Therapeutics initiated with an Outperform at Wolfe Research

Medium Report

Spyre Therapeutics initiated with an Outperform at Wolfe Research

Report

3/17

07:13 pm

syre

Spyre Therapeutics initiated with an Outperform at Wolfe Research

Medium Report

Spyre Therapeutics initiated with an Outperform at Wolfe Research

Report

2/18

04:38 am

syre